778 related articles for article (PubMed ID: 17521218)
1. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
Gutierrez-Dalmau A; Campistol JM
Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
3. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
4. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
Bhat M; Watt KD
Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
[TBL] [Abstract][Full Text] [Related]
5. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
Klintmalm GB; Saab S; Hong JC; Nashan B
Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
[TBL] [Abstract][Full Text] [Related]
6. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
7. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
[TBL] [Abstract][Full Text] [Related]
8. Malignancy in kidney transplant recipients.
Kapoor A
Drugs; 2008; 68 Suppl 1():11-9. PubMed ID: 18442297
[TBL] [Abstract][Full Text] [Related]
9. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
10. Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review.
Katabathina VS; Menias CO; Tammisetti VS; Lubner MG; Kielar A; Shaaban A; Mansour J; Surabhi VR; Hara AK
Radiographics; 2016; 36(5):1390-407. PubMed ID: 27618321
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
12. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
14. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
Geissler EK
Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
[TBL] [Abstract][Full Text] [Related]
15. New concepts and best practices for management of pre- and post-transplantation cancer.
Campistol JM; Cuervas-Mons V; Manito N; Almenar L; Arias M; Casafont F; Del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Román A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2012 Oct; 26(4):261-79. PubMed ID: 22902168
[TBL] [Abstract][Full Text] [Related]
16. Fighting malignancy in organ transplant recipients.
Geissler EK
Transplant Proc; 2009; 41(6 Suppl):S9-12. PubMed ID: 19651298
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of de novo malignancies after solid-organ transplantation: immunosuppression, infection and other risk factors.
Piselli P; Verdirosi D; Cimaglia C; Busnach G; Fratino L; Ettorre GM; De Paoli P; Citterio F; Serraino D
Best Pract Res Clin Obstet Gynaecol; 2014 Nov; 28(8):1251-65. PubMed ID: 25209964
[TBL] [Abstract][Full Text] [Related]
18. The role of proliferation signal inhibitors in post-transplant malignancies.
Gutiérrez-Dalmau A; Campistol JM
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i11-6. PubMed ID: 17360768
[TBL] [Abstract][Full Text] [Related]
19. Safety of mTOR inhibitors in adult solid organ transplantation.
Ventura-Aguiar P; Campistol JM; Diekmann F
Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
[TBL] [Abstract][Full Text] [Related]
20. The role of mTOR inhibitors in the management of posttransplant malignancy.
Monaco AP
Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]